Compare Badger Meter Inc (BMI) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Badger Meter Inc vs Recursion Pharmaceuticals Inc — how do they compare? Badger Meter Inc trades at $132.8 (market cap $3.93B), while Recursion Pharmaceuticals Inc trades at $3.3 (market cap $1.81B). The key difference: Badger Meter Inc is far larger — about 2.2× Recursion Pharmaceuticals Inc's market cap, and Badger Meter Inc pays a 1.18% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| BMI | RXRX | |
|---|---|---|
Market Cap | $3.93B | $1.81B |
Sector | Technology | Health |
52-Week High | $193.09 | $6.79 |
52-Week Low | $113.41 | $2.84 |
Enterprise Value | $3.84B | $1.33B |
Dividend Yield | 1.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Badger Meter (BMI) trades at $132.67, down 2.76% on the day, with a bearish technical signal and mixed earnings history. Key fundamentals include a P/E of 31.78, net income margin of 14.27%, and ROE of 18.48%. Recent news highlights insider buying and multiple class-action lawsuits, while cash flow trends show net outflows.
The outlook is cautious due to legal risks and earnings misses, but analyst consensus targets $155.20, implying upside. Risks include litigation and competitive pressures, while institutional interest and solid profitability offer some support.
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Badger Meter Inc
Badger Meter provides industry-leading water management solutions. Its smart measurement hardware and software analytics help water utilities and industrial customers optimize operations and conserve natural resources.
Read more on BMI →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
